----
Current ValuationThe current P/E ratio is -2.38, within the reasonable range, cheaper than 75.02% of the time in the past 5 years, and the industry ranks 28/78, the industry Median -4.79.
-2.38xP/E
HK$2.22Stock price
HK$-0.93Earnings per share
-2.38xP/E
Stock priceHK$2.22Earnings per shareHK$-0.93
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.39x
- Typical range
- -2.75x–-0.99x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0146292438584
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -68.88x | 75.55% | HK$76.70B |
09688HKZAI LAB | -14.73x | 432.84% | HK$21.73B |
01877HKJUNSHI BIO | -34.10x | 85.34% | HK$15.67B |
07666HKMETIS TECHBIO-P | -32.40x | 96.71% | HK$13.19B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
06855HKASCENTAGE | -6.03x | 18.76% | HK$10.20B |
01952HKEVEREST MED | -154.28x | 324.72% | HK$9.58B |
09606HKDUALITYBIO-B | -5.73x | 85.35% | HK$9.49B |
02595HKGENFLEET-B | -5.67x | 66.07% | HK$8.59B |
02493HKMABWELL-B | -6.66x | -- | HK$8.14B |
02616HKCSTONE PHARMA-B | -16.34x | 1.09% | HK$7.89B |
09887HKLEADS BIOLABS-B | -23.30x | 3.57% | HK$7.16B |
06938HKRIBOLIFE-B | -36.29x | 29.56% | HK$7.09B |
02171HKCARSGEN-B | -61.52x | 51.05% | HK$6.32B |
09966HKALPHAMAB-B | -29.64x | -- | HK$6.00B |
01672HKASCLETIS-B | -7.57x | 78.53% | HK$5.16B |
00775HKCKLIFE SCIENCES | -72.79x | -- | HK$4.71B |
02256HKABBISKO-B | -8.25x | 800.99% | HK$4.43B |
02335HKMICOT PHARMA-B | -9.17x | 37.52% | HK$3.85B |
01779HKLONGBIO-B | -15.35x | -- | HK$3.82B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
